# Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

> **NCT06824662** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Nader Sanai** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma WHO Grade IV

## Interventions

- **DRUG:** Quisinostat

## Key facts

- **NCT ID:** NCT06824662
- **Lead sponsor:** Nader Sanai
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-04
- **Primary completion:** 2026-07-15
- **Final completion:** 2028-01-14
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06824662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06824662, "Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06824662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*